Aclarion (ACON) shares rallied sharply early Monday after the healthcare technology company said it has established a commercial agreement with Scripps Health that will add its Nociscan technology platform to treat lower back pain to Scripps facilities in San Diego.
The agreement is expected to optimize Scripps' clinical treatment by providing Aclarion's magnetic resonance spectroscopy signal processing and allowing physicians to non-invasively distinguish between lumbar discs causing pain and non-painful discs, the companies said.
Financial terms were not disclosed.
Aclarion shares climbed by more than 125% in early trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.